Skip to main content

Anthrax Prevention

1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Altimmune
AltimmuneMD - Gaithersburg
1 program
1
NasoShieldPhase 12 trials
Active Trials
NCT04415749Completed43Est. Mar 2021
NCT03352466Completed145Est. May 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AltimmuneNasoShield
AltimmuneNasoShield

Clinical Trials (2)

Total enrollment: 188 patients across 2 trials

NasoShield in Healthy Adults to Study Safety and Immunogenicity

Start: Jun 2020Est. completion: Mar 202143 patients
Phase 1Completed

NasoShield Study of Safety and Immunogenicity

Start: Jan 2018Est. completion: May 2019145 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.